This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Xalkori® (crizotinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Resources

How to access Xalkori (crizotinib) for ROS1+ NSCLC 

Learn More

Video Resources

Learn More

PP-XLK-GBR-1172. March 2021

Indication

XALKORI as a monotherapy is indicated for:1

  • The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)

Register to receive tailored information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No